Table 2.
Demographic Data by Study Group
| Category | Sub-category | Group 0+7 IMVAMUNE1 Days 0, 7 (N=61) | Group 0+28 IMVAMUNE1 Days 0, 28 (N=67) | Group 0 IMVAMUNE1 Day 0 (N=63) | Placebo2 (N=17) | All Groups (N=208) |
|---|---|---|---|---|---|---|
| GENDER | Male | 36 (59.0%) | 31 (46.3%) | 31 (49.2%) | 9 (52.9%) | 107 (51.4%) |
| Female | 25 (41.0%) | 36 (53.7%) | 32 (50.8%) | 8 (47.1%) | 101 (48.6%) | |
| RACE | White | 52 (85.2%) | 57 (85.1%) | 54 (85.7%) | 15 (88.2%) | 178 (85.6%) |
| Black | 5 (8.2%) | 3 (4.5%) | 6 (9.5%) | 1 (5.9%) | 15 (7.2%) | |
| Asian | 0 | 2 (3.0%) | 2 (3.2%) | 1 (5.9%) | 5 (2.4%) | |
| Multiracial | 4 (6.6%) | 3 (4.5%) | 1 (1.6%) | 0 | 8 (3.8%) | |
| Not Reported | 0 | 2 (3.0%) | 0 | 0 | 2 (1.0%) | |
| ETHNICITY | Non-Hispanic/Latino | 59 (96.7%) | 64 (95.5%) | 60 (95.2%) | 16 (94.1%) | 199 (95.7%) |
| Hispanic/Latino | 2 (3.3%) | 3 (4.5%) | 3 (4.8%) | 1 (5.9%) | 9 (4.3%) | |
| AGE | Mean (S.D.) | 24.7 (4.6) | 25.0 (3.9) | 24.3 (3.9) | 25.4 (4.5) | 24.7 (4.2) |
| Median | 23 | 24 | 24 | 25 | 24 | |
| Range [Min., Max.] | [18, 35] | [18, 35] | [18, 35] | [19, 35] | [18, 35] |
1
Vaccine: IMVAMUNE 0.5 mL of 1× 108 cfu/mL administered subcutaneously on Days 0 and 7 (Group 0+ 7), Days 0 and 28 (Group 0+28) and Day 0 (Group 0).
2
Placebo: Saline 0.5 mL administered subcutaneously on Days 0 and 7 (Group 0+ 7, n= 6), Days 0 and 28 (Group 0+28, n=5) and Day 0 (Group 0, n=7).